Skip to main content
. Author manuscript; available in PMC: 2012 Aug 13.
Published in final edited form as: Gene Ther. 2006 Aug 10;14(1):58–67. doi: 10.1038/sj.gt.3302830

Figure 6.

Figure 6

(a) Therapeutic effect of intravenously injected Ad5.pK7-Δ24 in an orthotopic animal model of advanced hormone refractory breast cancer. GFP-expressing M4A4-LM3 cells were injected into the mammary fat pads of NMRI nude mice and primary tumors were allowed to grow for 10 days. Mice received two intravenous injections (3 × 1010 VP) of Ad5.pK7-Δ24, Ad5Δ24E3+ or no virus on days 10 and 33 (marked with an arrow) after the injection of cells (i.e. days 0 and 23 after treatment, respectively). Ad5.pK7-Δ24-treated mice had significantly fewer viable tumor cells on day 33 when compared to Ad5Δ24E3+ or mock-treated mice (P<0.05). Signal (photons) is depicted as a percentage of the initial photon count. (b) Biodistribution of Ad5.pK7 (GL) is similar to the isogenic Ad5 (GL) control. Bars denote s.e.